Sheikh Mujibullah, Saiyyad Arshiya, Aliunui Aimé, Jirvankar Pranita S
Datta Meghe College of Pharmacy DMIHER (Deemed to be University), Wardha, Maharashtra, 442001, India.
Med Oncol. 2025 May 2;42(6):190. doi: 10.1007/s12032-025-02746-w.
Oncolytic viruses (OVs) are a promising class of cancer therapy, exploiting their abilities to selectively infect and kill cancer cells while stimulating antitumor immune responses. The current assessment explores the changing horizons of OV immunotherapy, focusing on recent advances in technology plans to improve OV projects and combined approaches to improve curative efficacy. We discuss how OVs induce direct oncolysis and promote the release of tumor-associated antigens, leading to the activation of both innate and adaptive immunity. Special attention shall be given to programs for arm OVs to express curative genes, modify the tumor microenvironment and overcome immunosuppression. Moreover, we assess the synergies of uniting OVs with other immunotherapeutic techniques, such as immune checkpoint inhibitors and cell therapy, to improve tolerant outcomes. The present assessment provides an understanding of the relevant declaration of the OV analysis, highlighting the main obstacles and the future directions for the development of other capable and targeted cancer immunotherapy.
溶瘤病毒（OVs）是一类很有前景的癌症治疗手段，利用它们选择性感染和杀死癌细胞的能力，同时刺激抗肿瘤免疫反应。当前评估探讨了OV免疫疗法不断变化的前景，重点关注技术计划的最新进展，以改进OV项目以及提高疗效的联合方法。我们讨论了OVs如何诱导直接溶瘤并促进肿瘤相关抗原的释放，从而导致先天免疫和适应性免疫的激活。应特别关注武装OVs以表达治疗性基因、改变肿瘤微环境和克服免疫抑制的方案。此外，我们评估了将OVs与其他免疫治疗技术（如免疫检查点抑制剂和细胞疗法）联合以改善耐受结果的协同作用。本评估提供了对OV分析相关声明的理解，突出了主要障碍以及其他有能力且有针对性的癌症免疫治疗发展的未来方向。
